Recipient-based approach to tailoring immunosuppression in liver transplantation (Q37771615)

22 August 2017

1 reference

title

Recipient-based approach to tailoring immunosuppression in liver transplantation (English)

1 reference

22 August 2017

1 reference

liver transplantation

1 reference

N Kemmer

1 reference

22 August 2017

G Neff

series ordinal

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Transplantation Proceedings

22 August 2017

published in

1 reference

22 August 2017

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

1731-1737

1 reference

Immunosuppression in liver transplantation

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Transplantation immunology: what the clinician needs to know for immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Indications of mycophenolate mofetil in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Racial disparities in renal transplant outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Pharmacokinetics of immunosuppressants: a perspective on ethnic differences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Racial variation in dosage requirements of tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Decreased effect of immunosuppression on immunocompetence in African--Americans after kidney and liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Incidence of acute rejection in African-American liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Factors affecting variability in distribution of tacrolimus in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Genetic contribution to variable human CYP3A-mediated metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Tacrolimus dose in black renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver transplantation trends for older recipients: regional and ethnic variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Our experience in liver transplantation in patients over 65 yr of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver transplantation in patients over sixty years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver transplantation in recipients over 65 yr old: a single center experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Clinical relevance of age-related immune dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Changes in immune function with age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Age and immune response in organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Pharmacokinetic considerations relating to tacrolimus dosing in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Cyclosporin pharmacokinetics in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Rejection and recipient age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Age and liver transplantation: a report of the Liver Transplantation Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Impact of age-related immune dysfunction on risk of infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Transplantation in autoimmune liver diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Long-term outcome of liver transplantation for autoimmune hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

INCREASED INCIDENCE OF CHRONIC REJECTION IN ADULT PATIENTS TRANSPLANTED FOR AUTOIMMUNE HEPATITIS: ASSESSMENT OF RISK FACTORS1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Recurrence of autoimmune liver disease after liver transplantation: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Mycophenolate mofetil for the treatment of primary sclerosing cholangitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Guidelines on the management of osteoporosis associated with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Influence of steroids on HCV recurrence after liver transplantation: A prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Hepatitis B virus DNA contains a glucocorticoid-responsive element

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Antiretroviral and immunosuppressive drug-drug interactions: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.02.076

10.1016/J.TRANSPROCEED.2010.02.076

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference